The renin-angiotensin system: a therapeutic target in atrial fibrillation

Area of Science:

• Cardiology
• Pharmacology
• Electrophysiology

Background:

• The renin-angiotensin system (RAS) is increasingly implicated in the development of atrial fibrillation (AF).
• Experimental models show RAS-dependent mechanisms contribute to AF substrates.
• Clinical observations support a link between RAS and AF pathophysiology.

Purpose of the Study:

• To review experimental and clinical evidence on the role of the RAS in AF pathogenesis.
• To evaluate the efficacy of RAS inhibition in managing AF.

Main Methods:

• Review of experimental animal data on RAS and AF.
• Analysis of clinical studies investigating RAS blockade for AF prevention and management.
• Synthesis of evidence from diverse patient populations.

Main Results:

• Experimental data indicate RAS-dependent pathways create AF substrates.
• Clinical studies demonstrate RAS blockade prevents new-onset and recurrent AF.
• Effective use of RAS blockade is shown in patients with hypertension, left ventricular hypertrophy, heart failure, and post-cardioversion.

Conclusions:

• The RAS is a significant factor in AF pathogenesis.
• RAS inhibition is an effective strategy for managing and preventing AF across various clinical scenarios.